Back
Eli Lilly and Co (LLY)
PharmaceuticalsLLY · NEW YORK STOCK EXCHANGE, INC. · USD
New to investing? How to read this page →$1235.56
+2.96%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$22.95
ROE
107.5%
Gross margin
82.8%
Debt/Equity
1.39x
Revenue growth
55.5%
Eli Lilly and Co — company intelligence
Earnings surprises
Q1 2026$8.55 vs $6.73 est+27.0%
Q4 2025$7.54 vs $6.74 est+11.9%
Q3 2025$7.02 vs $5.75 est+22.0%
Q2 2025$6.31 vs $5.51 est+14.5%
Analyst consensus · 38 analysts
30 Buy7 Hold1 Sell
Updated Jul 7, 2026
Insider activity · 90 days
12 buys3 sellsnet -18,200 shares
Fyrwald J ErikBuy 9 · Jun 15, 2026
Alvarez RalphBuy 11 · Jun 15, 2026
Sulzberger GabrielleBuy 4 · Jun 15, 2026
Recent SEC filings
4 — Insider transaction reportJun 16, 2026
4 — Insider transaction reportJun 16, 2026
4 — Insider transaction reportJun 16, 2026
Latest news
NVO Rallies 11% in a Month: How Should Investors Play the Stock? — Yahoo · 20h ago
B of A Securities Maintains Buy on Eli Lilly, Raises Price Target to $1334 — Benzinga · 20h ago
Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN — Yahoo · 1d ago
Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma — Yahoo · 1d ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Eli Lilly and Co
Weekly undervalued picks (like LLY)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.